Sugi Predict

Sugi Predict / Compounds / SCHEMBL2009694

SCHEMBL2009694

SCHEMBL2009694

Cc1csc(S(N)(=O)=O)c1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 17/20 0.58
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ CCNE1 P24864 1/20 0.45
▸ CDK2 P24941 1/20 0.45
▸ CDK5 Q00535 1/20 0.45
▸ CDK5R1 Q15078 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23569830 0.83 CA2 (0.42) CA2CA12CA1CA9CCNE1
SCHEMBL27452903 0.78 CA2 (0.53) CA2CA12CA1CA9CCNE1
SCHEMBL3100175 0.77 DAO (0.43) CA2CA12CA1CA9ALDH1A1
SCHEMBL1127299 0.77 DAO (0.39) CA2CA12CA1CA9ALDH1A1
Hydrochloric Acid SCHEMBL27830652 0.76 DAO (0.42) CA2ALDH1A1
SCHEMBL2008068 0.74 CA2 (0.52) CA2CA12CA1CA9
SCHEMBL5149907 0.74 CA2 (0.52) CA2CA12CA1CA9CCNE1
SCHEMBL28047295 0.74 CA2 (0.59) CA2
SCHEMBL5511547 0.74 CA2 (0.52) CA2CA12CA1CA9CCNE1
SCHEMBL23531742 0.73 CA2 (0.50) CA2CA12CA1CA9CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024115549-A1 ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-06 — — WO claimed
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use Oxford Drug Design Limited (GB) 2025-03-11 — — US disclosed
CN-114846000-B 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2025-01-03 — — CN disclosed
WO-2024115549-A1 ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-06 — — WO disclosed
CN-117177973-A Pyrido [3,2-D ] pyrimidine compounds and their use for the treatment of proliferative disorders 蒙特利尔大学 2023-12-05 — — CN disclosed
WO-2023211990-A1 BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2023-11-02 — — WO disclosed
WO-2023193733-A1 AT2R AGONIST 武汉人福创新药物研发中心有限公司 2023-10-12 — — WO disclosed
US-20230234921-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-07-27 — — US disclosed
US-20230114875-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2023-04-13 — — US disclosed
EP-4077289-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2022-10-26 — — EP disclosed
CN-1863789-A Substituted isoquinolinones PORTOLA PHARM INC (US) 2006-11-15 — — CN disclosed
US-20060223871-A1 Thiophene-and thiazolesulfonamides as antineoplastic agents GROSSMAN CORA S 2006-10-05 — — US disclosed
EP-1442030-B1 THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS LILLY CO ELI (US) 2006-08-30 — — EP disclosed
US-7084170-B2 Thiophene-amd thiazolesulfonamides as antineoplastic agents ELI LILLY AND COMPANY (US) 2006-08-01 — — US disclosed
EP-1667989-A1 SUBSTITUTED ISOQUINOLINONES Portola Pharmaceuticals, Inc. (US) 2006-06-14 — — EP disclosed
US-20050113399-A1 Substituted isoquinolinones PORTOLA PHARMACEUTICALS, INC. (US) 2005-05-26 — — US disclosed
WO-2005035520-A1 SUBSTITUTED ISOQUINOLINONES PORTOLA PHARMACEUTICALS, INC. (US) 2005-04-21 — — WO disclosed
US-20040198784-A1 Thiophene-amd thiazolesulfonamides as antineoplastic agents GROSSMAN CORA SUE (US) 2004-10-07 — — US disclosed
EP-1442030-A1 THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS ELI LILLY AND COMPANY (US) 2004-08-04 — — EP disclosed
WO-2003035629-A1 THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS ELI LILLY AND COMPANY (US) 2003-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use AARS1, ASNS, GARS1 CA2 2761/4885CA12 4371/4885CA1 4200/4885
US-20050113399-A1 Substituted isoquinolinones PFKP, MPL, TBXA2R CA2 4801/4885CA12 4880/4885CA1 4876/4885
US-20230234921-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF SERPINB1, CTSV, CTSE CA2 736/4885CA12 559/4885CA1 259/4885
US-20060223871-A1 Thiophene-and thiazolesulfonamides as antineoplastic agents TPMT, TST, MGMT CA2 1394/4885CA12 290/4885CA1 1002/4885
US-20040198784-A1 Thiophene-amd thiazolesulfonamides as antineoplastic agents ALDH1A2, MGMT, NR2E3 CA2 2965/4885CA12 2289/4885CA1 4169/4885
US-20230114875-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AARS1, ASNS, GARS1 CA2 2761/4885CA12 4371/4885CA1 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.